Diffusion-weighted magnetic resonance imaging to assess diffuse renal pathology: a systematic review and statement paper.

Caroli, Anna; Schneider, Moritz; Friedli, Iris; Ljimani, Alexandra; De Seigneux, Sophie; Boor, Peter; Gullapudi, Latha; Kazmi, Isma; Mendichovszky, Iosif A; Notohamiprodjo, Mike; Selby, Nicholas M; Thöny, Harriet C.; Grenier, Nicolas; Vallée, Jean-Paul (2018). Diffusion-weighted magnetic resonance imaging to assess diffuse renal pathology: a systematic review and statement paper. Nephrology, dialysis, transplantation, 33(suppl_2), ii29-ii40. Oxford University Press 10.1093/ndt/gfy163

CMI-3-173.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (443kB) | Preview

Diffusion-weighted magnetic resonance imaging (DWI) is a non-invasive method sensitive to local water motion in the tissue. As a tool to probe the microstructure, including the presence and potentially the degree of renal fibrosis, DWI has the potential to become an effective imaging biomarker. The aim of this review is to discuss the current status of renal DWI in diffuse renal diseases. DWI biomarkers can be classified in the following three main categories: (i) the apparent diffusion coefficient-an overall measure of water diffusion and microcirculation in the tissue; (ii) true diffusion, pseudodiffusion and flowing fraction-providing separate information on diffusion and perfusion or tubular flow; and (iii) fractional anisotropy-measuring the microstructural orientation. An overview of human studies applying renal DWI in diffuse pathologies is given, demonstrating not only the feasibility and intra-study reproducibility of DWI but also highlighting the need for standardization of methods, additional validation and qualification. The current and future role of renal DWI in clinical practice is reviewed, emphasizing its potential as a surrogate and monitoring biomarker for interstitial fibrosis in chronic kidney disease, as well as a surrogate biomarker for the inflammation in acute kidney diseases that may impact patient selection for renal biopsy in acute graft rejection. As part of the international COST (European Cooperation in Science and Technology) action PARENCHIMA (Magnetic Resonance Imaging Biomarkers for Chronic Kidney Disease), aimed at eliminating the barriers to the clinical use of functional renal magnetic resonance imaging, this article provides practical recommendations for future design of clinical studies and the use of renal DWI in clinical practice.

Item Type:

Journal Article (Review Article)


04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Institute of Diagnostic, Interventional and Paediatric Radiology

UniBE Contributor:

Thöny, Harriet C.


600 Technology > 610 Medicine & health




Oxford University Press




Isabelle Ursula Saurer

Date Deposited:

07 Mar 2019 15:30

Last Modified:

01 Nov 2019 14:28

Publisher DOI:


PubMed ID:






Actions (login required)

Edit item Edit item
Provide Feedback